Earnings call transcript: The a2 Milk posts strong sales but softer profit in H2 2026

The a2 Milk Company reported FY2026 revenue up 12.4% to NZD 1.972 billion, but reported EBITDA fell 2.5% to NZD 284.4 million due to China supply chain disruption (China label formula revenue -14% y/y). Underlying EBITDA rose 5.4% to NZD 307.6 million, yet gross margin narrowed to 47.7% (down 340 bps) and management guided FY2027 EBITDA margin at ~15% with revenue growth in the mid-single digits and a second-half weighting. The stock was little changed (+0.21% to $4.78), reflecting strong sales momentum offset by weaker reported profitability and cautious near-term margin/inventory recovery.

Analysis

The market is treating this as a clean supply reset, but the harder problem is customer loss, not inventory normalization. In infant formula, early-stage users are the least recoverable cohort, so the earnings path depends on re-acquisition economics, not just “product back on shelf.” That means the next 1-3 months are about proving conversion and repeat purchase, while the 6-18 month question is whether the franchise permanently ceded premium shelf space to rivals that absorbed the pantry stock.

Margin guidance also matters more than the headline revenue beat. The mix shift toward liquid milk and nutritionals helps top line, but it dilutes group gross margin because the core formula business is where pricing power and operating leverage live. Pokeno is a medium-term positive only if it genuinely lowers structural supply risk; until then, it is another fixed-cost layer that can keep reported EBITDA noisy and cap rerating even if underlying demand stabilizes. Synlait is not the obvious loser from one quarter of disruption, but it does lose bargaining power as a2 internalizes more capacity and diversifies manufacturing.

The consensus risk is that investors may be overconfident in a fast recovery because brand sentiment and search interest improved. Those are leading indicators, but not substitutes for off-take and door recovery; the bear case is that marketing intensity has to stay elevated for longer than guided, forcing gross margin to remain under pressure. Falsifiers: China label off-take reaccelerating above ~60% of pre-shock levels by the next update, or FY27 H1 margins tracking above the implied run-rate with no further trade-down in pricing.

Key Decisions for Investors

• ACOPF: Do not chase the stock on the initial post-earnings drift. Wait for the next AGM / quarterly sell-through update; add only if China label off-take moves materially above the current recovery trend and H1 FY27 gross margin holds near guidance.
• ACOPF: If the shares rally back toward the upper half of the 52-week range before recovery data improves, consider a 3-6 month put spread or outright hedge. Risk/reward favors downside if re-acquisition stalls and marketing spend stays elevated.
• ACOPF: For long-only accounts, treat this as a staged position rather than a full-size core holding. The upside case is a slower rerate from mid-single-digit growth plus Pokeno efficiency; the downside is another reset if early-stage users do not return.
• SMLKF: Put on the watchlist as a relative-value indicator on supply-chain normalization, but do not short mechanically yet. The trade only works if a2’s insourcing reduces Synlait leverage faster than Synlait can backfill volume.
• Monitor the next 1-3 months for two falsifiers: China label off-take >60% of pre-disruption run-rate, or English label momentum re-accelerating without incremental discounting. If both happen, cover hedges and reassess upside.